Pulminiq Benefit Could Be Confirmed With Placebo Trial, Cmte. Members Say
Executive Summary
Chiron should confirm a potential survival benefit seen with Pulminiq in a Phase II trial of lung transplant patients with a randomized, placebo-controlled trial, members of FDA's Pulmonary-Allergy Drugs Advisory Committee said